ArticlePsychiatry and clinical psychopharmacology2025
Efficacy of Concurrent Utilization of Mannitol and Nimodipine in Treating Hypertensive Intracerebral Hemorrhage and Its Effects on Neurological Function.
Article in Psychiatry and clinical psychopharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Efficacy of nimodipine plus mannitol in the treatment of cerebral edema after intracerebral hemorrhage and its impact on cerebral hemodynamic parameters.American journal of translational research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The goal of this study was to retrospectively appraise the efficacy of the combined therapy comprising mannitol and nimodipine for hypertensive intracerebral hemorrhage (HICH) and its impact on neurological function. Methods: The study subjects encompassed 100 individuals with HICH who were admitted to the hospital from May 2021 to 2023 and were categorized into a control group and an observation group, with 50 individuals comprising each group. Intravenous mannitol infusion was administered to the control group, while the observation group received nimodipine injection in combination with mannitol, followed by a course of oral nimodipine tablets. Both groups of patients were treated for 3 months. A comparative analysis was performed to assess the clinical efficacy, neurological function, hematoma volume, serum inflammatory cytokine levels, hemodynamic parameters, and incidence of adverse reactions across the 2 groups. Results: A remarkably higher overall response rate of 92.00% was observed in the treatment group as opposed to 74.00% in the control group, with both groups exhibiting noteworthy reductions in National Institutes of Health Stroke Scale scores post-treatment, and the reduction being more pronounced in the treatment group ( Conclusion: The concurrent administration of mannitol and nimodipine in HICH presents substantial advantages, including enhanced clinical efficacy, improved neurological function, decreased hematoma volume, and regulation of hemodynamic parameters. This treatment approach has shown significant efficacy and is worthy of widespread promotion and application in clinical practice.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.